Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risks and benefits of vancomycin use in infected adult inpatients
RBR-4zrwtzRecruiting
- Sponsor
- Departamento de Clínica Médica da Faculdade de Medicina de Botucatu
- Start
- Jun 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vancomycin in bacterial disease and sepsis (3 arms), sponsored by Departamento de Clínica Médica da Faculdade de Medicina de Botucatu. Primary endpoints: Development of acute kidney injury and Mortality. Started Jun 2017; status: recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial diseasesepsis
Beyond the preview
Go deeper on RBR-4zrwtz.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4zrwtz.